人口和并发症障碍在症治疗修订:一个全民调查
André Idegård1,2, David Larsson1,2,3, Johan Zelano1,2,3
1Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Brain and behavior
|October 21, 2025
概括
一半的患者对他们的第一个抗发作药物 (ASM) 没有反应. 患有和痴呆症等并发症的老年人不太可能接受治疗修订,这表明有护理缺口.
科学领域:
- 神经学 神经学
- 公共卫生 公共卫生
- 药物治疗 药物治疗
背景情况:
- 第一线抗发作药物 (ASM) 治疗在约50%的病例中失败.
- 确定影响ASM治疗修订的因素对于优化管理至关重要.
- 全人口数据可以揭示在获得足够的随访护理方面的差异.
研究的目的:
- 调查患者人口统计和并发症对初始ASM单疗改的可能性的影响.
- 确定病护理和随访方面的潜在缺口.
主要方法:
- 利用瑞典国家登记册来识别发生性的成年患者 (2007-2019).
- 定义的治疗修订是改变药物或启动第二个ASM.
- 采用考克斯的比例危险模型来分析与治疗修订相关的因素.
主要成果:
- 这项研究包括44,185名个人.
- 高龄,脑血管疾病和痴呆症与ASM治疗修订的可能性较低有关.
- 女性,脑部感染患者和脑瘤患者的治疗修改可能性更高.
结论:
- 患有的老年人和患有脑血管疾病或痴呆症等并发症的老年人不太可能接受最初的ASM修订.
- 这表明当前的医疗保健系统对这些患者群体存在潜在的不利因素.
- 需要进一步的研究来解决治疗和随访方面的这些差异.
相关概念视频
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Electroconvulsive Therapy
864
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
864
Drug Therapy
239
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
239
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
814
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
814
Antiepileptic Drugs: Potassium Channel Activators
631
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
631
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K


